Header Logo

Connection

SALIM VIRANI to Primary Prevention

Back to Details
This is a "connection" page, showing publications SALIM VIRANI has written about Primary Prevention.
SALIM VIRANI
Connection Strength
6.618
Primary Prevention
  1. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. Prog Cardiovasc Dis. 2021 Sep-Oct; 68:2-6.
    View in: PubMed
    Score: 0.683
  2. 2018 Cholesterol Guidelines: Key Topics in Primary Prevention. Curr Atheroscler Rep. 2019 03 16; 21(5):17.
    View in: PubMed
    Score: 0.579
  3. Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding. Evid Based Med. 2016 12; 21(6):225.
    View in: PubMed
    Score: 0.490
  4. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20; 65(2):111-21.
    View in: PubMed
    Score: 0.434
  5. Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths. Tex Heart Inst J. 2013; 40(3):288-9.
    View in: PubMed
    Score: 0.376
  6. Going from Primary to Primordial Prevention: Is the Juice Worth the Squeeze? Curr Cardiol Rep. 2024 Oct; 26(10):1135-1143.
    View in: PubMed
    Score: 0.210
  7. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease. Circulation. 2023 05 02; 147(18):1411-1413.
    View in: PubMed
    Score: 0.190
  8. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey. Prog Cardiovasc Dis. 2022 Nov-Dec; 75:78-82.
    View in: PubMed
    Score: 0.184
  9. Guideline-Concordant Statin Therapy Use?in Secondary Prevention: Should the Medical Community Wait for Divine Intervention? J Am Coll Cardiol. 2022 05 10; 79(18):1814-1817.
    View in: PubMed
    Score: 0.180
  10. Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry. Circ Cardiovasc Qual Outcomes. 2022 03; 15(3):e007979.
    View in: PubMed
    Score: 0.177
  11. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
    View in: PubMed
    Score: 0.172
  12. Epidemiology and risk factors for stroke in young individuals: implications for prevention. Curr Opin Cardiol. 2021 09 01; 36(5):565-571.
    View in: PubMed
    Score: 0.172
  13. Contemporary outcomes studies to identify and mitigate the risk in patients with premature cardiovascular disease. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):559-570.
    View in: PubMed
    Score: 0.165
  14. High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. J Am Heart Assoc. 2020 02 04; 9(3):e013600.
    View in: PubMed
    Score: 0.154
  15. Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside. Prog Cardiovasc Dis. 2019 Sep - Oct; 62(5):406-413.
    View in: PubMed
    Score: 0.151
  16. Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. Eur J Prev Cardiol. 2020 10; 27(15):1597-1605.
    View in: PubMed
    Score: 0.148
  17. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. Curr Atheroscler Rep. 2019 06 22; 21(9):32.
    View in: PubMed
    Score: 0.147
  18. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 09 10; 140(11):e563-e595.
    View in: PubMed
    Score: 0.145
  19. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 09 10; 140(11):e596-e646.
    View in: PubMed
    Score: 0.145
  20. Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry). Am J Cardiol. 2019 04 01; 123(7):1011-1018.
    View in: PubMed
    Score: 0.143
  21. Use of Risk Assessment Tools to?Guide?Decision-Making in the?Primary?Prevention of Atherosclerotic?Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019 06 25; 73(24):3153-3167.
    View in: PubMed
    Score: 0.141
  22. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Circulation. 2019 06 18; 139(25):e1162-e1177.
    View in: PubMed
    Score: 0.141
  23. Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. J Am Heart Assoc. 2018 09 18; 7(18):e009251.
    View in: PubMed
    Score: 0.140
  24. Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Heart Assoc. 2018 06 13; 7(12).
    View in: PubMed
    Score: 0.137
  25. Life's Simple 7 and the risk of atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2018 08; 275:174-181.
    View in: PubMed
    Score: 0.137
  26. Statin Use and Adverse Effects Among Adults >75?Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc. 2018 05 08; 7(10).
    View in: PubMed
    Score: 0.136
  27. Epidemiologic studies targeting primary cardiovascular disease prevention in South Asia. Indian Heart J. 2018 Sep - Oct; 70(5):721-730.
    View in: PubMed
    Score: 0.134
  28. Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity. Curr Atheroscler Rep. 2016 Jan; 18(1):4.
    View in: PubMed
    Score: 0.116
  29. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020. Eur J Prev Cardiol. 2022 10 20; 29(14):1830-1838.
    View in: PubMed
    Score: 0.046
  30. Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. J Am Coll Cardiol. 2022 03 01; 79(8):757-768.
    View in: PubMed
    Score: 0.044
  31. Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circ Cardiovasc Qual Outcomes. 2021 09; 14(9):e007485.
    View in: PubMed
    Score: 0.043
  32. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. J Am Coll Cardiol. 2020 08 18; 76(7):781-793.
    View in: PubMed
    Score: 0.040
  33. Sex Differences in the Use of Statins in Community Practice. Circ Cardiovasc Qual Outcomes. 2019 08; 12(8):e005562.
    View in: PubMed
    Score: 0.037
  34. Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J. 2019 08; 214:113-124.
    View in: PubMed
    Score: 0.037
  35. Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiol. 2019 05 01; 4(5):473-477.
    View in: PubMed
    Score: 0.036
  36. Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. J Am Heart Assoc. 2019 04 02; 8(7):e011765.
    View in: PubMed
    Score: 0.036
  37. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular?Disease: A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines. J Am Coll Cardiol. 2019 09 10; 74(10):e177-e232.
    View in: PubMed
    Score: 0.036
  38. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines. J Am Coll Cardiol. 2019 09 10; 74(10):1376-1414.
    View in: PubMed
    Score: 0.036
  39. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA Cardiol. 2018 08 01; 3(8):739-748.
    View in: PubMed
    Score: 0.035
  40. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. J Clin Lipidol. 2018 Mar - Apr; 12(2):367-374.e3.
    View in: PubMed
    Score: 0.033
  41. Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 10; 253:156-163.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.